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Ricco and his colleagues have written a sobering and in some
ways shocking article that describes the overall French experience
with endovascular aortic aneurysm repair (EVAR) during a two-
year period ending in May 2001. Their report is sobering because
it documents how poor EVAR results are in a countrywide expe-
rience. Thirty-day and 1-year mortality and complication rates
were surprisingly high. This article, therefore, raises questions
about some favorable trial data and published single-center re-
ports, which may be biased by patient selection and other factors so
that they are not reflective of the mortality and morbidity for
EVAR in general, a conclusion also supported by much of the
Eurostar experience. Articles such as this one should raise a sober-
ing note of caution about the overenthusiastic widespread adop-
tion of EVAR, particularly for good-risk young patients with small
abdominal aortic aneurysms (AAAs).
More importantly, this article is a shocking reflection of how
poorly physicians and surgeons conform with rules and regulations
when faced with an exciting new technology. A surprising number
of surgeons were even willing to break the law in this French study.
More than 80% of the EVAR cases were performed outside of a
required research protocol and without documentation of the
required informed consent. Shocking also was the fact that 19% of
the patients received absolutely no follow-up after EVAR. Equally
disturbing was the frequent performance of EVAR on so many
patients with AAAs 50 mm in diameter or less. Forty-seven percent
of the patients in the study fell into this category, and 30% had an
AAA less than 50 mm.
The chaotic approach described in this article provides strong
support for current stringent US Food and Drug Administration
(FDA) rules. Perhaps these rules should be in force for longer
periods than the mandatory 1- to 2-year follow-up currently re-
quired for appealing new high-tech implantable technology.
Although the article by Ricco et al describes a French experi-
ence, it is likely that physician and surgeon behavior is not going to
differ greatly on this side of the Atlantic. Thus, the findings in this
article suggest that PMA approval of an exciting new device in the
United States may be followed by abusive use similar to that in
France. This possibility lends further support to lengthening the
period of FDA oversight with new endovascular devices. The rush
for physicians to adopt attractive new technology and commercial
issues may not always be in the best interests of patients, particu-
larly when other good therapeutic alternatives exist. This must
certainly be kept in mind when dealing with small aneurysms and
other asymptomatic vascular lesions.
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